A Phase 2 interventional study of Whole-body resistance training and aerobic exercise in Metastatic Breast Cancer, sponsored by University of Utah. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by University of Utah · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Breast Neoplasms by University of Utah — 9 open to participants now, 9 under way, 1 of them phase 3. Breast Neoplasms · University of Utah.
Among the 33 studies in Breast Neoplasms by University of Utah, this one is the 11th largest by planned enrollment, is one of 8 that started in 2025, is one of 7 in phase 2, and was the 33rd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →9 of the 33 studies in Breast Neoplasms by University of Utah are open now, in 1 country. Recruiting first, the newest first:
University of Utah · Sites in United States
Ages 18+ · Women only · Healthy volunteers
University of Utah · Sites in United States
Ages 18+
University of Utah · Sites in United States
Ages 18+ · Women only
University of Utah · Sites in United States
Ages 18+ · Women only
University of Utah · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 2 · Phase 4 1
First in 2006; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 34 across the 33 interventional studies. Of the 22 that completed or were terminated, 6 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Utah is the lead sponsor of 997 studies on the registry; 176 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 69 (61%) have results posted.
6 of the studies in Breast Neoplasms by University of Utah that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07166042Phase 3University of UtahGuided Meditation During Radiation Therapy for Breast and Gynecological Malignancies | 2027-11 |
| NCT05464082University of UtahFunctional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC | 2026-12-30 |
| NCT05291507University of UtahFeasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System | 2027-01 |
| NCT07044583University of UtahSAVE Trial: SAfe Opioid Use Video Education | 2027-08 |
| NCT07120100University of UtahTranscranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Survivors | 2027-09-15 |
Add all 6 to your calendar (.ics) → With an account.
Among the 33 studies in Breast Neoplasms by University of Utah, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to test the efficacy of using a 12-week, home-based, unsupervised aerobic and resistance training exercise program for changes in cancer-related fatigue in patients with metastatic breast cancer who are receiving Enhertu.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-Currently adhering to national physical activity guidelines for resistance training, as defined as participating in structured resistance training ≥ two days per week.
AND Currently participating in structured moderate-intensity aerobic exercise for ≥ 150 minutes per week.
Aerobic exercise includes, but is not limited to, walking, swimming, cycling, running, rowing, hiking, and elliptical.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Whole-body resistance training and aerobic exercise
A 12-week individualized, home-based, unsupervised, whole-body resistance training and aerobic exercise routine will be provided to each study participant.
Change in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue score from baseline to Week 13 (end of exercise intervention).
Test the preliminary efficacy of a 12-week, home-based, unsupervised aerobic and resistance training exercise program on changes in cancer-related fatigue, in patients with a diagnosis of locally advanced/unresectable or metastatic breast cancer and patients with High-Risk HER 2+ breast cancer after completion of neoadjuvant chemotherapy who are receiving Enhertu therapy. FACIT Fatigue Scored 0 (not at all)- 4(Very Much).
Time frame: 13 weeks
Feasibility defined as greater than 75% of all participants completing greater than 66% of all prescribed workouts from baseline to Week 13.
Test the feasibility of the tested 12-week, home-based, unsupervised aerobic and resistance training exercise program.
Time frame: 13 weeks
Mean Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue score measured every three weeks from baseline to Week 13.
Compare the trajectory of cancer-related fatigue from baseline to Week 13 between patients receiving the exercise intervention versus not. FACIT Fatigue Scored 0 (not at all)- 4 (Very Much).
Time frame: 13 weeks
Change in Functional Assessment of Cancer Therapy - Breast (FACT-B) score from baseline to Week 13.
Evaluate the preliminary efficacy of the exercise intervention on breast cancer-related quality of life. FACT-B scored 0 (not at all)- 4 (Very Much).
Time frame: 13 weeks
Mean Functional Assessment of Cancer Therapy - Breast (FACT-B) score measured every three weeks from baseline to 13 weeks after initiation of training.
Compare the trajectory of breast cancer-related quality of life from baseline to Week 13 after initiation of training between patients receiving the exercise intervention versus not. FACT-B scored 0 (not at all)- 4 (Very Much).
Time frame: 13 weeks
Change in the average time spent in moderate to vigorous physical activity (in minutes)
Evaluate the preliminary efficacy of the exercise intervention on exercise engagement. At one week prior to baseline (i.e. baseline), at the midpoint of the intervention (Week 6) and during the final week of the intervention (Week 12), as measured by the Actigraph GT9x Link accelerometer.
Time frame: 12 weeks
Markers evaluating activity collected from the Actigraph, such as time spent in light activity.
Evaluate the preliminary efficacy of the exercise intervention on exercise engagement.
Time frame: 12 weeks
Markers evaluating activity collected from the Actigraph, such as step count.
Evaluate the preliminary efficacy of the exercise intervention on exercise engagement.
Time frame: 12 weeks
Average time spent in moderate to vigorous physical activity (in minutes) measured at baseline, Week 6, and Week 12 by the Actigraph GT9x Link accelerometer.
Compare the trajectory of exercise engagement from baseline to 12 weeks between patients receiving the exercise intervention versus not.
Time frame: 12 weeks
Other markers evaluating activity collected daily from the Actigraph GT9x, such as step count.
Compare the trajectory of exercise engagement from baseline to 12 weeks between patients receiving the exercise intervention versus not.
Time frame: 12 weeks
Other markers evaluating activity collected daily from the Actigraph GT9x, such as time spent in light activity.
Compare the trajectory of exercise engagement from baseline to 12 weeks between patients receiving the exercise intervention versus not.
Time frame: 12 weeks
Change in mean PROMIS Physical Function score from baseline to Week 13.
Evaluate the preliminary efficacy of the exercise intervention on physical function. Scored 5 (Without any difficulty)- 1 (Unable to do).
Time frame: 13 weeks
Change in the following objective measures of physical function from baseline to Week 13: 30-second chair stand.
Evaluate the preliminary efficacy of the exercise intervention on physical function.
Time frame: 13 weeks
Change in the following objective measures of physical function from baseline to Week 13: Balance Test
Evaluate the preliminary efficacy of the exercise intervention on physical function. The Balance Test will consist of: Participants will be instructed to stand up with their feet in three different positions (side-by-side, tandem and semi-tandem) for 10 seconds each position.
Time frame: 13 weeks
Change in the following objective measures of physical function from baseline to Week 13: 30-second maximum push-up test.
Evaluate the preliminary efficacy of the exercise intervention on physical function.
Time frame: 13 weeks
Average physical function measured at baseline, Week 6, and Week 12 by PROMIS Physical Function score.
Compare the trajectory of physical function from baseline to 12 weeks between patients receiving the exercise intervention versus not. Scored 5 (Without any difficulty)- 1 (Unable to do).
Time frame: 12 weeks
Other markers evaluating physical function, including 30-second chair stand.
Compare the trajectory of physical function from baseline to 12 weeks between patients receiving the exercise intervention versus not.
Time frame: 12 weeks.
Other markers evaluating physical function, including a Balance Test.
Compare the trajectory of physical function from baseline to 12 weeks between patients receiving the exercise intervention versus not. The Balance Test will consist of: Participants will be instructed to stand up with their feet in three different positions (side-by-side, tandem and semi-tandem) for 10 seconds each position.
Time frame: 12 weeks.
Other markers evaluating physical function, including a 30-second maximum push-up test.
Compare the trajectory of physical function from baseline to 12 weeks between patients receiving the exercise intervention versus not.
Time frame: 12 weeks.
Change in Sit-to-Stand score patterns as measured by actigraphy (central measure of fatigue) from baseline to Week 13.
Evaluate the preliminary efficacy of the exercise intervention on measures of peripheral and central fatigue.
Time frame: 13 weeks
Change in handgrip strength (peripheral measures of fatigue) patterns as measured by actigraphy (central measure of fatigue) from baseline to Week 13.
Evaluate the preliminary efficacy of the exercise intervention on measures of peripheral and central fatigue.
Time frame: 13 weeks
Change in the number of rest-activity patterns as measured by actigraphy (central measure of fatigue) from baseline to Week 13.
Evaluate the preliminary efficacy of the exercise intervention on measures of peripheral and central fatigue.
Time frame: 13 weeks
Mean score for sit-to-stand patterns measured at baseline, 6-weeks, and Week 13.
Compare the trajectory of measures of peripheral and central fatigue baseline to Week 13 after initiation of training between patients receiving the exercise intervention versus not.
Time frame: 13 weeks
Mean score for handgrip strength patterns measured at baseline, 6-weeks, and Week 13.
Compare the trajectory of measures of peripheral and central fatigue baseline to Week 13 after initiation of training between patients receiving the exercise intervention versus not.
Time frame: 13 weeks
Mean number of rest-activity patterns measured at baseline, 6-weeks, and Week 13.
Compare the trajectory of measures of peripheral and central fatigue baseline to Week 13 after initiation of training between patients receiving the exercise intervention versus not.
Time frame: 13 weeks
Started Nov 2025 (actual). Primary completion is estimated for Nov 2027, 24 months after the start.
Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 24 months is below that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.